within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EX02_Sorafenib;

model Sorafenib
  extends Pharmacolibrary.Drugs.ATC.L.L01EX02;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>L01EX02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Sorafenib is a multikinase inhibitor approved for the treatment of advanced renal cell carcinoma, unresectable hepatocellular carcinoma, and differentiated thyroid carcinoma. It acts by inhibiting tumor cell proliferation and angiogenesis.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult cancer patients (solid tumors), both male and female, after multiple oral doses.</p><h4>References</h4><ol><li><p>Bakrim, S, et al., &amp; Bouyahya, A (2022). Health Benefits and Pharmacological Properties of Stigmasterol. <i>Antioxidants (Basel, Switzerland)</i> 11(10) –. DOI:<a href=\"https://doi.org/10.3390/antiox11101912\">10.3390/antiox11101912</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36290632/\">https://pubmed.ncbi.nlm.nih.gov/36290632</a></p></li><li><p>Tran, HT, et al., &amp; Nagasaki, Y (2022). Sorafenib-loaded silica-containing redox nanoparticles for oral anti-liver fibrosis therapy. <i>Journal of controlled release : official journal of the Controlled Release Society</i> 345 880–891. DOI:<a href=\"https://doi.org/10.1016/j.jconrel.2022.04.002\">10.1016/j.jconrel.2022.04.002</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35395328/\">https://pubmed.ncbi.nlm.nih.gov/35395328</a></p></li><li><p>Hussaarts, KGAM, et al., &amp; Bins, S (2020). Influence of Probenecid on the Pharmacokinetics and Pharmacodynamics of Sorafenib. <i>Pharmaceutics</i> 12(9) –. DOI:<a href=\"https://doi.org/10.3390/pharmaceutics12090788\">10.3390/pharmaceutics12090788</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32825359/\">https://pubmed.ncbi.nlm.nih.gov/32825359</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Sorafenib;
